Earnings call transcript: Kitron ASA reports record Q1 2026 results

Kitron delivered record Q1 2026 results, with revenue up 65.7% year-over-year to NOK 272.7 million, EBIT more than doubling to NOK 26 million, and EPS rising to $0.09 from $0.04. Defense and Aerospace revenue tripled to NOK 137 million and now represents about half of group revenue, while backlog hit a record near NOK 806 million and book-to-bill was 1.35. Management said the company is trending toward the upper half of prior 2026 guidance, though supply chain timing and ramp-up inefficiencies capped margin upside; the stock rose 5.61% on the release.

Analysis

The key second-order signal is not simply stronger defense demand; it is that defense is now funding the operational scaling curve for the rest of the business. Once a contract manufacturer gets a larger share of mix from long-cycle, high-visibility defense programs, it can amortize automation, QA, and regional footprint expansion across a much higher base, which should mechanically lift returns even if headline margins stay in a mid-to-high single digit band. That makes the current quarter less about one-off earnings power and more about a step-change in earning capacity over the next 4-8 quarters.

The market is likely underappreciating the inventory-to-revenue conversion risk embedded in the guidance cadence. A book-to-bill above 1 and a record backlog are supportive, but when growth is this fast, a single quarter of supplier slippage or labor onboarding friction can create an earnings miss even if demand remains intact. That means the stock can trade like a momentum name in the next 1-2 quarters, but the fundamental path will likely be lumpier than consensus models assume, especially if management continues to prioritize capacity build over near-term margin maximization.

The bigger competitive implication is that Kitron is starting to look like a beneficiary of European rearmament and electrification localization rather than a generic EMS provider. That should pressure smaller regional peers that lack multi-site flexibility, defense accreditation, or the ability to absorb program ramps across Europe and the U.S. The market may also be too cautious on the duration of the defense tailwind: if prime contractors keep pushing program decisions earlier, backlog quality improves, but so does the optionality on 2027-2028 revenue, which is where valuation re-rating comes from.

Key Decisions for Investors

• Go long KITROn/Kitron shares on pullbacks over the next 1-3 weeks; use a staggered entry and a 6-9 month horizon. Risk/reward favors upside if management converts backlog without further supply-chain drag, but trim if margin guidance is not revised upward after Q2.
• Pair trade: long Kitron vs short a broader industrials/EMS basket over 3-6 months. The thesis is that defense-linked backlog and regional capacity scarcity should outperform generalist manufacturing names that lack the same backlog visibility.
• Buy a call spread in KITRON-style exposure if liquid, targeting the next 2 earnings dates. Structure for moderate upside: benefit if the market re-rates on Q2 confirmation, with defined downside if execution stumbles.
• Avoid chasing after the immediate earnings pop; wait for the next operational checkpoint. If Q2 shows continued backlog growth and margin re-acceleration, add aggressively; if not, the stock likely needs a digestion period as investors re-price working-capital and staffing risk.
• Relative-value short against a defense-exposed competitor with weaker backlog conversion or lower local manufacturing footprint, if available in the same market. The winner should be the name with the best combination of defense mix, regional flexibility, and balance-sheet room to keep investing.